^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Merkel Cell Carcinoma
    Regimen:
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/02/2019
    Excerpt:
    Merkel Cell Carcinoma: Preferred regimen...Useful in certain circumstances as clinical judgment dictates for patients with contraindications to checkpoint immunotherapy...Cisplatin±Etoposide